Back to top
more

CVS Health (CVS)

(Delayed Data from NYSE)

$66.63 USD

66.63
12,908,298

-0.22 (-0.33%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $66.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 7% (233 out of 250)

Industry: Retail - Pharmacies and Drug Stores

Better trading starts here.

Zacks News

CVS Health (CVS) Gains As Market Dips: What You Should Know

CVS Health (CVS) closed the most recent trading day at $71.99, moving +1.82% from the previous trading session.

CVS Health's (CVS) New COVID-19 Vaccine Available at Its Stores

CVS Health's (CVS) updated mRNA COVID-19 vaccine is now available at all its pharmacy locations.

CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know

CVS Health (CVS) closed at $70.24 in the latest trading session, marking a -0.4% move from the prior day.

Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.

CVS Health (CVS) Gains As Market Dips: What You Should Know

CVS Health (CVS) closed the most recent trading day at $65.60, moving +0.14% from the previous trading session.

CVS Health (CVS) Down 12.3% Since Last Earnings Report: Can It Rebound?

CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock

CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CVS Health's (CVS) Cordavis to Focus on Biosimilar Products

CVS Health's (CVS) wholly owned subsidiary, Cordavis, is set to bring high-quality biosimilar products to the market.

The Zacks Analyst Blog Highlights Merck, Philip Morris, Qualcomm, CVS Health and Chubb

Merck, Philip Morris, Qualcomm, CVS Health and Chubb are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Merck, Philip Morris & QUALCOMM

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Philip Morris International Inc. (PM) and QUALCOMM Incorporated (QCOM).

Is Trending Stock CVS Health Corporation (CVS) a Buy Now?

CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

Investors are optimistic about CVS Health's (CVS) continued growth across the insured and self-insured medical, pharmacy, dental and behavioral health products and services.

Walgreens (WBA) and VillageMD Expand Partnership in Chicago

Walgreens (WBA) and VillageMD's coordinated primary care and pharmacy services are now available in Chicago.

CVS Health (CVS) Q2 Earnings Surpass Estimates, Margins Up

Pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health drive CVS Health's (CVS) Q2 revenues.

Private Sector Jobs Come in Higher Than Expected

Private Sector Jobs Come in Higher Than Expected.

Mark Vickery headshot

ADP Jobs +324K Still Higher than Expected; CVS, KHC, HUM Report

ADP Chief Economist Nela Richardson said, "The economy is doing better than expected... we continue to see a slowdown in pay growth without broad-based job loss."

CVS Health (CVS) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for CVS Health (CVS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

CVS Health (CVS) Tops Q2 Earnings and Revenue Estimates

CVS Health (CVS) delivered earnings and revenue surprises of 4.25% and 2.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?

We expect brand price inflation, new product launch, higher utilization and new PBM clients to have contributed to second-quarter growth for CVS Health (CVS).

Earnings Preview: CVS Health (CVS) Q2 Earnings Expected to Decline

CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know

CVS Health (CVS) closed at $75.95 in the latest trading session, marking a +1.2% move from the prior day.

Zacks Industry Outlook Highlights CVS Health, Herbalife, Rite Aid and Amazon

CVS Health, Herbalife, Rite Aid and Amazon have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Headwinds

The Zacks Retail Pharmacy and Drugstore industry players like CVS, HLF and RAD are likely to gain despite reimbursement challenges hurting the overall industry health.

CVS Health (CVS) Outpaces Stock Market Gains: What You Should Know

CVS Health (CVS) closed at $72.31 in the latest trading session, marking a +1.6% move from the prior day.